Press Releases

• 5/19/2013
  Cubist Achieves Top Biotech Ranking in Globe 100 List
• 5/8/2013
  Cubist to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
• 5/7/2013
  FDA Grants Fast Track Designation for Cubist’s Late-Stage Antibiotic Candidate
• 4/18/2013
  Cubist Pharmaceuticals Reports First Quarter 2013 Financial Results
• 4/11/2013
  Cubist to Announce First Quarter 2013 Financial Results on Thursday, April 18th, 2013
• 4/9/2013
  Cubist Pharmaceuticals and the New England Patriots Radio Network Honor Lynn, Massachusetts Biology Teacher
• 3/11/2013
  Cubist Obtains Remaining Rights to Ceftolozane from Astellas
• 3/4/2013
  Cubist Announces Appointment of Michael Tomsicek to Chief Financial Officer
• 2/28/2013
  FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
• 2/27/2013
  Cubist Pharmaceuticals to Present at Cowen and Company 33rd Annual Health Care Conference
• 2/25/2013
  Cubist Announces Exclusive Option to Acquire Adynxx
• 1/29/2013
  Cubist to Present at February Investor Conferences
• 1/23/2013
  Cubist Reports Fourth Quarter and Full Year 2012 Financial Results
• 1/8/2013
  Cubist to Appoint Tom DesRosier as Senior Vice President, Chief Legal Officer and Secretary
• 1/7/2013
  Cubist Announces Full-Year 2012 Revenues and Provides Business Update

View Press Release Archive

• 9/06/2011
  ADOLOR CORPORATION ANNOUNCES COMPLETION OF ACQUISITION OF FULL OWNERSHIP OF ENTEREG(R) (ALVIMOPAN)
• 8/10/2011
  ADOLOR CORPORATION ANNOUNCES POSITIVE RESULTS FROM PHASE 2 PROGRAM IN OIC
• 6/14/2011
  ADOLOR CORPORATION ANNOUNCES AGREEMENT TO ACQUIRE FULL OWNERSHIP OF ENTEREG (ALVIMOPAN)
• 6/06/2011
  ADOLOR CORPORATION COMPLETES ENROLLMENT IN PHASE 2 OIC PROGRAM
• 1/10/2011
  ADOLOR CORPORATION EXPANDS PHASE 2 OPIOID INDUCED CONSTIPATION PROGRAM
• 11/03/2010
  MEDICATION USE EVALUATION OF ENTEREG (ALVIMOPAN) PUBLISHED IN THE NOVEMBER EDITION OF THE ANNALS OF PHARMACOTHERAPY
• 10/19/2010
  ADOLOR CORPORATION INITIATES PHASE 2 OIC STUDY OF ADL5945
• 11/12/2009
  ADOLOR CORPORATION INITIATES CLINICAL TESTING IN OPIOID BOWEL DYSFUNCTION PROGRAM
• 9/21/2009
  ADOLOR ACQUIRES RIGHTS TO CLINICAL-STAGE PRODUCT CANDIDATE FROM ELI LILLY AND COMPANY
• 8/20/2009
  PHARMACOECONOMIC ANALYSIS OF REPORTED USE OF ENTEREG(R) (ALVIMOPAN) PUBLISHED IN AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
• 11/18/2008
  STUDY PUBLISHED IN ARCHIVES OF SURGERY DEMONSTRATED BENEFIT OF ENTEREG(R) (ALVIMOPAN) IN POSTOPERATIVE ILEUS
• 9/02/2008
  ADOLOR REGAINS RIGHTS TO ENTEREG(R) (ALVIMOPAN) FOR OBD
• 7/24/2008
  ADOLOR PROVIDES ENTEREG(R) (ALVIMOPAN) HOSPITAL REGISTRATION UPDATE
• 7/03/2008
  ADOLOR PROVIDES UPDATE ON ENTEREG(R) (ALVIMOPAN) OBD PROGRAM
• 6/09/2008
  ENTEREG(R) (ALVIMOPAN) AVAILABLE FOR THE MANAGEMENT OF POSTOPERATIVE ILEUS
• 5/20/2008
  ADOLOR AND GLAXOSMITHKLINE ANNOUNCE FDA APPROVAL OF ENTEREG(R) (ALVIMOPAN) FOR THE MANAGEMENT OF POSTOPERATIVE ILEUS (POI)
• 1/23/2008
  ADOLOR AND GLAXOSMITHKLINE REPORT FAVORABLE FDA ADVISORY COMMITTEE MEETING FOR ENTEREG(R) (ALVIMOPAN) FOR THE MANAGEMENT OF POSTOPERATIVE ILEUS IN BOWEL RESECTION
• 1/18/2008
  ADOLOR ANNOUNCES AVAILABILITY OF BRIEFING DOCUMENTS FOR JANUARY 23RD FDA ADVISORY COMMITTEE MEETING ON ENTEREG(R) (ALVIMOPAN)
• 11/28/2007
  ADOLOR AND GLAXOSMITHKLINE ANNOUNCE FDA ADVISORY COMMITTEE TO REVIEW ENTEREG(R) (ALVIMOPAN) FOR THE MANAGEMENT OF POSTOPERATIVE ILEUS (POI)
• 8/28/2007
  FDA ACCEPTS FOR REVIEW COMPLETE RESPONSE TO APPROVABLE LETTER FOR ENTEREG(R) (ALVIMOPAN) FOR POI
• 6/11/2007
  GSK AND ADOLOR UPDATE ALVIMOPAN (ENTEREG/ENTRAREG(R)) DEVELOPMENT PROGRAM
• 4/09/2007
  GSK AND ADOLOR ANNOUNCE PRELIMINARY RESULTS FROM PHASE 3 SAFETY STUDY OF ALVIMOPAN (ENTEREG/ENTRAREG(R))